Medical

According to Genoa Pharmaceuticals, a pre-clinical study conducted at McMaster University demonstrated that the company's GP-101 inhaled pirfenidone demonstrated statistically significant greater anti-fibrotic effect in an in vivo model of pulmonary fibrosisi than did higher doses of oral pirfenidone. Genoa said that it would present data at an upcoming pulmonary … [Read more...] about Inhaled pirfenidone shows greater efficacy than oral in pre-clinical study

A new consortium described as a "series of conceptual research projects in the area of nasal physiology, function and drug delivery" that "aims to enhance understanding in the area of upper respiratory tract disorders and develop methodological approaches that can be utilized via the wider scientific community" has been announced. Researchers involved in the … [Read more...] about New nasal research consortium “The Oz Nose Project” announced

A study presented at ATS 2013 found that over 40 percent of uninsured patients treated for COPD at a US clinic did not actually have COPD. Researchers from Northeast Ohio Medical University and Saint Elizabeth Health Center in Youngstown assessed 80 patients at a health center in Akron, Ohio using spirometry. All of the patients had either been diagnosed with COPD or … [Read more...] about Study shows significant overdiagnosis of COPD

Prosonix has started a Phase 2 safety and dose-ranging study of PSX1002 inhaled glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), in patients with moderate-to-severe COPD, the company has announced. The suspension formulation of PSX1002 engineered particles is delivered by pMDI. Prosonix CEO David Hipkiss commented, “This trial with PSX1002 is a … [Read more...] about Prosonix begins Phase 2 study of inhaled glycopyrronium bromide

According to Sunovion Pharmaceuticals, data from a year-long clinical trial comparing the safety of Brovana arformoterol tartrate inhalation solution versus placebo in patients with moderate-to-severe COPD show no increased risk of exacerbations or death due to a respiratory event. Fewer than 10% of patients treated with 15 mcg of Brovana twice daily had serious … [Read more...] about Safety studies show no increased risk with use of Brovana inhalation solution

Pearl Therapeutics has announced the initiation of a Phase 3 program called PINNACLE for its PT003 glycopyrrolate/formoterol fumarate metered dose inhaler for patients with moderate-to-severe COPD. The program will include two studies involving more than 2,700 patients in North America, Europe, Australia, and New Zealand. Enrollment is expected to be complete by … [Read more...] about Pearl Therapeutics initiates Phase 3 program for LAMA/LABA MDI

Almirall and Forest Labs have announced positive results from the Phase 3 AUGMENT/COPD study of their fixed dose combination aclidinium bromide/formoterol fumarate dry powder inhaler in patients with COPD. The announcement followed several weeks after the companies announced positive results from another Phase 3 study of aclidinium/formoterol, the ACLIFORM/COPD study. … [Read more...] about More positive Phase 3 results for aclidinium/formoterol DPI

Novartis's QVA149 indacaterol maleate/glycopyrronium DPI demonstrated 15% greater reduction in all COPD exacerbations compared to glycopyrronium and 14% compared to tiotropium according to study results published April 23 2013 in Lancet Respiratory Medicine. QVA149 reduced moderate-to-severe exacerbations by 12% over glycopyrronium. The study also showed improved lung … [Read more...] about QVA149 data demonstrates superior reduction of COPD exacerbations compared to glycopyrronium alone